DOI: https://doi.org/10.22141/2224-0551.2.1.62.1.2015.83277

Experience of Using Ursodeoxycholic Acid in Children with Organic Diseases of the Liver

Ye.N. Babadzhanian

Abstract


The mechanisms of ursodeoxycholic acid effects on the human body, the findings of clinical studies and observations on the use of ursodeoxycholic acid preparation for the treatment of children with organic diseases of the liver were considered.


Keywords


ursodeoxycholic acid; children; organic diseases of the liver

References


Cheng K., Ashby D., Smyth R. Ursodeoxycholic acid for Cystic Fibrosis-related liver disease (Cochrane Review) // The Cochrane Library, Cochrane Database Syst. Rev. — 2014 Dec 15. — 12. — CD000222. — Doi: 10.1002/14651858.CD000222.pub3.

Ghany et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases // Hepatology. — 2011 Oct. — № 54(4). — Р. 1433–44. — Doi: 10.1002/hep.24641.

Nunnari G., Pinzone M.R., Cacopardo B. Lack of clinical and histological progression of chronic hepatitis C in individuals with true persistently normal ALT: the result of a 17-year follow-up // J. Viral. Hepat. — 2013, Apr. — № 20(4). — e131-7. — Doi: 10.1111/jvh.12029.

Okada K., Shoda J., Taguchi K. Ursodeoxycholic acid stimulates Nrf2_mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice //Am. J. Physiol. Gastrointest. Liver Physiol. — August 7, 2008. — Doi:10.1152/ajpgi.90321.2008.

Pinheiro N.C. et al. Refractory pruritus in primary biliary cirrhosis // BMJ Case Rep. — 2013 Nov. — № 14. — Pii: bcr2013200634. doi: 10.1136/bcr-2013-200634.

Silverio A.O. et al. Are the spider angiomas skin mar­kers of hepatopulmonary syndrome? // Arq. Gastroenterol. — 2013 Jul — Sep. — Vol. 50(3). — Р. 175-179. — Doi: 10.1590/S0004-28032013000200031.

Guarino M.P., Cocca S., Altomare A. et al. UDCA in the treatment of diseases of the gallbladder: unfinished the story // World J. Gastroenterol. — 2013 Aug 21. — № 19(31). — Doi: 10.3748/wjg.v19.i31.5029.

Uto H., Mawatari S., Kumagai K. et al. Clinical features of hepatitis C virus carriers with persistently normal alanine aminotransferase levels // Hepat. Mon. — 2012, Feb. — № 12(2). — Р. 77-84. — Doi: 10.5812/hepatmon.829.

Wunsch E., Trottier J., Milkiewicz M., Raszeja-Wyszomirska J. et al. The consequences of the abolition of UDCA in patients with primary sclerosing cholangitis // Hepatology. — 2014 Feb 12. — Doi: 10.1002/hep.27074.

Герок В., Блюм Х.Е. Заболевания печения и желчевыделительной системы: Пер. с нем. — М., 2009.

Дитяча гастроентерологія. Підручник / Бєлоусов Ю.В., Бєлоусова О.Ю., Бабаджанян О.М., Волошина Л.Г. та ін. — Харкі‑в, 2013. — 520 с.

Эль-Райфе Н., Готтранд Ф. Роль урсодезоксихолевой кислоты в лечении холестаза у детей // Consilium medicum Ukraina. — 2008. — № 10.

Циммерман С. Первичный склерозирующий холангит: современные представления // Клиническая медицина. — 2014. — № 1. — С. 5–10.






Copyright (c) 2016 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2019

 

   Seo анализ сайта